Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Breast Cancer | Research

Clinical significance of low expression of CADM3 in breast cancer and preliminary exploration of related mechanisms

Authors: Huiyang Ren, Zhen Wang, Lei Zhang, Guolian Zhu, Feng Li, Bo Chen

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Cell adhesion molecule 3 (CADM3), a transmembrane glycoprotein on cell membranes, plays a role in the way of ligand and receptor interaction. However, there are few studies on CADM3 in tumors, and how it works in breast cancer (BC) remains unclear.

Methods

The Cancer Genome Atlas (TCGA) database and clinical samples were used to analyze CADM3 expression and its correlation with clinicopathological factors and prognosis. Its correlation with immune infiltration was analyzed by TCGA. The effects of CADM3 on proliferation and migration were investigated by cell clonal formation, CCK-8, cell scratch and transwell assay. Protein interaction network was prepared and the function prediction of related genes was conducted. The correlation between CADM3 and MAPK pathway was further explored by western blot experiment.

Results

The expression of CADM3 in BC tissues were significantly lower than that in adjacent normal tissues. High level of CADM3 was related to better prognosis of BC patients. CADM3 was an independent prognostic factor for BC. Expression of CADM3 was significantly associated with the status of ER and PR, age and PAM50 subtypes. CADM3 positively related to many immune infiltrating cells. Overexpression of CADM3 can notably reduce cell proliferation and migration. CADM3 was related to MAPK pathway and the phosphorylation of ERK1/2 and JNK1 was inhibited in BC cells with high CADM3.

Conclusions

Our research reveals the clinical significance of CADM3 in BC and indicates the critical roles of CADM3 in immune infiltration and MAPK pathway.
Appendix
Available only for authorised users
Literature
1.
SUNG H, FERLAY J, SIEGEL RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries [J]. Cancer J Clin. 2021;71(3):209–49.CrossRef
2.
3.
ELANGBAM C S, QUALLS C W JR. DAHLGREN R R. Cell adhesion molecules–update [J]. Vet Pathol. 1997;34(1):61–73.PubMedCrossRef
4.
EDELMAN G M. Cell adhesion molecules in the regulation of animal form and tissue pattern [J]. Annu Rev Cell Biol. 1986;2:81–116.PubMedCrossRef
5.
TAKAI Y. Nectin and Afadin: novel organizers of intercellular junctions [J]. J Cell Sci. 2003;116(Pt 1):17–27.PubMedCrossRef
6.
SI X, XU F, XU F, et al. CADM1 inhibits ovarian cancer cell proliferation and migration by potentially regulating the PI3K/Akt/mTOR pathway [J]. Volume 123. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie; 2020. p. 109717.
7.
BOTLING J, EDLUND K, LOHR M, et al. Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation [J]. Clin cancer Research: Official J Am Association Cancer Res. 2013;19(1):194–204.CrossRef
8.
CHANG H, MA M, MA R, et al. Folate deficiency and aberrant expression of cell adhesion molecule 1 are potential indicators of prognosis in laryngeal squamous cell carcinoma [J]. Oncol Lett. 2016;12(6):4510–4.PubMedPubMedCentralCrossRef
9.
CAI Q, ZHU A. GONG L. Exosomes of glioma cells deliver miR-148a to promote proliferation and metastasis of glioblastoma via targeting CADM1 [J]. Bulletin du cancer, 2018, 105(7–8): 643– 51.
10.
CHEN Y, LIU L, GUO Z, et al. Lost expression of cell adhesion molecule 1 is associated with bladder cancer progression and recurrence and its overexpression inhibited tumor cell malignant behaviors [J]. Oncol Lett. 2019;17(2):2047–56.PubMed
11.
HIROHASHI S, KANAI Y. Cell adhesion system and human cancer morphogenesis [J]. Cancer Sci. 2003;94(7):575–81.PubMedCrossRef
12.
BOLES KS, BARCHET W, DIACOVO T, et al. The tumor suppressor TSLC1/NECL-2 triggers NK-cell and CD8 + T-cell responses through the cell-surface receptor CRTAM [J]. Blood. 2005;106(3):779–86.PubMedCrossRef
13.
OBERNDORFER F, MüLLAUER L. Molecular pathology of lung cancer: current status and perspectives [J]. Curr Opin Oncol. 2018;30(2):69–76.PubMedCrossRef
14.
FUJITO T, IKEDA W. Inhibition of cell movement and proliferation by cell-cell contact-induced interaction of Necl-5 with nectin-3 [J]. J Cell Biol. 2005;171(1):165–73.PubMedPubMedCentralCrossRef
15.
LOVE M I, HUBER W. Moderated estimation of Fold change and dispersion for RNA-seq data with DESeq2 [J]. Genome Biol. 2014;15(12):550.PubMedCrossRef
16.
ROBINSON MD, MCCARTHY D J, SMYTH, G K. Bioinf (Oxford England). 2010;26(1):139–40. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data [J].
17.
HäNZELMANN S, CASTELO R. BMC Bioinformatics. 2013;14:7. GUINNEY J. GSVA: gene set variation analysis for microarray and RNA-seq data [J].
18.
BINDEA G, MLECNIK B. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer [J]. Immunity. 2013;39(4):782–95.PubMedCrossRef
19.
SZKLARCZYK D, GABLE A L, LYON D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets [J]. Nucleic Acids Res. 2019;47(D1):D607–13.PubMedCrossRef
20.
CHIN C H, CHEN S H, WU H H, et al. cytoHubba: identifying hub objects and sub-networks from complex interactome [J]. BMC Syst Biol. 2014;8(Suppl 4):S11.PubMedPubMedCentralCrossRef
21.
WARDE-FARLEY D, DONALDSON S L, COMES O et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function [J]. Nucleic Acids Res, 2010, 38(Web Server issue): W214–20.
22.
23.
24.
KARAGIANNIS GS, JONES J G GOSWAMIS, et al. Signatures of breast cancer metastasis at a glance [J]. J Cell Sci. 2016;129(9):1751–8.PubMedPubMedCentral
25.
26.
AHMAD A. Pathways to breast cancer recurrence [J]. ISRN oncology. 2013, 2013: 290568.
27.
LU H, GUO Y, GUPTA G, et al. Mitogen-activated protein kinase (MAPK): new insights in breast Cancer [J]. J Environ Pathol Toxicol Oncology: Official Organ Int Soc Environ Toxicol Cancer. 2019;38(1):51–9.CrossRef
28.
BLATTER S, ROTTENBERG S. Minimal residual disease in cancer therapy–small things make all the difference [J]. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy, 2015, 21–2: 1–10.
29.
MURAKAMI Y. Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human oncogenesis [J]. Cancer Sci. 2005;96(9):543–52.PubMedCrossRef
30.
XU C, LIU R, ZHANG Q, et al. The diversification of evolutionarily conserved MAPK cascades correlates with the evolution of Fungal species and Development of lifestyles [J]. Genome Biol Evol. 2017;9(2):311–22.PubMed
31.
ZHANG Y, SMOLEN P, BAXTER D A et al. Biphasic regulation of p38 MAPK by Serotonin contributes to the efficacy of stimulus protocols that induce long-term synaptic facilitation [J]. eNeuro, 2017, 4(1).
32.
JOHNSON GL. The c-jun kinase/stress-activated pathway: regulation, function and role in human disease [J]. Biochim Biophys Acta. 2007;1773(8):1341–8.PubMedPubMedCentralCrossRef
33.
CUI J, ZHANG M, ZHANG Y Q, et al. JNK pathway: diseases and therapeutic potential [J]. Acta Pharmacol Sin. 2007;28(5):601–8.PubMedCrossRef
34.
DHILLON A S, HAGAN S, RATH O, et al. MAP kinase signalling pathways in cancer [J]. Oncogene. 2007;26(22):3279–90.PubMedCrossRef
35.
LEE S, RAUCH J. KOLCH W. Targeting MAPK signaling in Cancer: mechanisms of Drug Resistance and sensitivity [J]. Int J Mol Sci, 2020, 21(3).
36.
AVRUCH J. MAP kinase pathways: the first twenty years [J]. Biochim Biophys Acta. 2007;1773(8):1150–60.PubMedCrossRef
37.
SIVARAMAN VS, WANG H, NUOVO G J, et al. Hyperexpression of mitogen-activated protein kinase in human breast cancer [J]. J Clin Investig. 1997, 99(7):1478–83.PubMedPubMedCentralCrossRef
38.
MUELLER H, FLURY N, EPPENBERGER-CASTORI S, et al. Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients [J]. Int J Cancer. 2000;89(4):384–8.PubMedCrossRef
39.
JERJEES D A, ALABDULLAH M, ALKAABI M, et al. ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer [J]. Breast Cancer Res Treat. 2014;147(1):25–37.PubMedCrossRef
40.
MILDE-LANGOSCH K, BAMBERGER A M, RIECK G, et al. Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer [J]. Br J Cancer. 2005;92(12):2206–15.PubMedCrossRef
41.
KUO H T, HSU H T, CHANG C C, et al. High nuclear phosphorylated extracellular signal-regulated kinase expression associated with poor differentiation, larger tumor size, and an advanced stage of breast cancer [J]. Pol J Pathology: Official J Pol Soc Pathologists. 2013;64(3):163–9.CrossRef
42.
NAKOPOULOU L, MYLONA E, RAFAILIDIS P et al. Effect of different ERK2 protein localizations on prognosis of patients with invasive breast carcinoma [J]. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica, 2005, 113(10): 693–701.
43.
CAI H, MIAO M. Mir-214-3p promotes the proliferation, migration and invasion of osteosarcoma cells by targeting CADM1 [J]. Oncol Lett. 2018;16(2):2620–8.PubMedPubMedCentral
44.
WANICZEK D, LORENC Z, ŚNIETURA M et al. Tumor-Associated Macrophages and Regulatory T Cells Infiltration and the clinical outcome in Colorectal Cancer [J]. Archivum Immunologiae et therapiae experimentalis, 2017, 65(5): 445–54.
45.
LYU L, YAO J, WANG M, et al. Overexpressed pseudogene HLA-DPB2 promotes Tumor Immune infiltrates by regulating HLA-DPB1 and indicates a better prognosis in breast Cancer [J]. Front Oncol. 2020;10:1245.PubMedPubMedCentralCrossRef
46.
47.
MAHMOUD S M, PAISH E C, POWE D G, et al. Tumor-infiltrating CD8 + lymphocytes predict clinical outcome in breast cancer [J]. J Clin Oncology: Official J Am Soc Clin Oncol. 2011;29(15):1949–55.CrossRef
48.
ALI H, R, PROVENZANO E, DAWSON S J, et al. Association between CD8 + T-cell infiltration and breast cancer survival in 12,439 patients [J]. Annals Oncology: Official J Eur Soc Med Oncol. 2014;25(8):1536–43.CrossRef
49.
GU-TRANTIEN C, LOI S. CD4+ follicular helper T cell infiltration predicts breast cancer survival [J]. J Clin Investig. 2013;123(7):2873-92.PubMedCrossRef
50.
BROZ ML, BINNEWIES M. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity [J]. Cancer Cell. 2014;26(5):638–52.PubMedPubMedCentralCrossRef
51.
SáNCHEZ-PAULETE A R, CUETO F J, MARTíNEZ-LóPEZ M, et al. Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 monoclonal antibodies requires BATF3-Dependent dendritic cells [J]. Cancer Discov. 2016;6(1):71–9.CrossRef
52.
SCHAAF M B, GARG A D AGOSTINISP. Defining the role of the tumor vasculature in antitumor immunity and immunotherapy [J]. Volume 9. Cell death & disease; 2018. p. 115. 2.
53.
KIM H W, KIM J E, HWANG M H, et al. Enhancement of natural killer cell cytotoxicity by sodium/iodide symporter gene-mediated radioiodine pretreatment in breast cancer cells [J]. PLoS ONE. 2013;8(8):e70194.PubMedPubMedCentralCrossRef
54.
NELSON B H. CD20 + B cells: the other tumor-infiltrating lymphocytes [J]. J Immunol (Baltimore Md: 1950). 2010;185(9):4977–82.CrossRef
55.
IGLESIA MD, VINCENT B G, PARKER JS, et al. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer [J]. Clin cancer Research: Official J Am Association Cancer Res. 2014;20(14):3818–29.CrossRef
56.
PONCIN A, ONESTI C E, JOSSE C et al. Immunity and breast Cancer: focus on eosinophils [J]. Biomedicines, 2021, 9(9).
57.
XU Y, WU Y, ZHANG S, et al. A tumor-specific Super-enhancer drives Immune Evasion by Guiding Synchronous expression of PD-L1 and PD-L2 [J]. Cell Rep. 2020;32(4):108000.PubMedCrossRef
58.
MA P, JIN X, FAN Z, et al. Super-enhancer receives signals from the extracellular matrix to induce PD-L1-mediated immune evasion via integrin/BRAF/TAK1/ERK/ETV4 signaling [J]. Cancer Biology Med. 2021;19(5):669–84.CrossRef
59.
HENRY K E, MACK K N NAGLEVL, et al. ERK Inhibition improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma [J]. Mol Cancer Ther. 2021;20(10):2026–34.PubMedCrossRef
Metadata
Title
Clinical significance of low expression of CADM3 in breast cancer and preliminary exploration of related mechanisms
Authors
Huiyang Ren
Zhen Wang
Lei Zhang
Guolian Zhu
Feng Li
Bo Chen
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12114-y

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Development and validation of a 18F-FDG PET/CT radiomics nomogram for predicting progression free survival in locally advanced cervical cancer: a retrospective multicenter study

Research

A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam

Research

Investigating the causal role of the gut microbiota in esophageal cancer and its subtypes: a two-sample Mendelian randomization study

Research

Radiation pneumonitis after concurrent aumolertinib and thoracic radiotherapy in EGFR-mutant non-small cell lung cancer patients

Research

Cancer diagnosis after emergency presentations in people with mental health and substance use conditions: a national cohort study

Research

NUSAP1 promotes pancreatic ductal adenocarcinoma progression by drives the epithelial-mesenchymal transition and reduces AMPK phosphorylation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits